Galmed Pharmaceuticals Ltd.
EOCN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595353
No open-market purchases or sales by Galmed Pharmaceuticals Ltd. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $85.9K in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Galmed Pharmaceuticals Ltd. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 15 | 14 | −1 |
| Shares | 76.0K | 72.8K | −3.16K (−4.2%) |
| Value | $140.2K | $102.0K | −$38.2K (−27.2%) |
New holders (3)
Institutions that held Galmed Pharmaceuticals Ltd. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 50,492 | $71.2K | 0.00% |
| Two Sigma Investments, LP | 21,200 | $29.3K | 0.00% |
| Wealthspire Advisors, LLC | 21 | $29 | 0.00% |
Sold out (4)
Institutions that held Galmed Pharmaceuticals Ltd. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Schonfeld Strategic Advisors LLC | 23,194 | $42.7K |
| Cambridge Investment Research Advisors, Inc. | 10,132 | $19.0K |
| UMA Financial Services, Inc. | 23 | $43 |
| Raymond James Financial Inc | 12 | $22 |